Adia Nutrition Inc. said its subsidiary Adia Med of Winter Park, LLC submitted a final revised protocol to an Institutional Review Board for a lower back pain clinical study of AdiaVita. The company said the study is designed as a single-blind, placebo-controlled trial with about 100 participants and includes a crossover phase, and noted that Adia Med is also running an IRB-approved 24-month Autism Spectrum Disorder study that is actively recruiting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603031020NEWSFILECNPR____20260303_286105_1) on March 03, 2026, and is solely responsible for the information contained therein.